Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative thymosin alpha 1 plus capecitabine for prevention of hepatocellular carcinoma recurrence
ChiCTR-TRC-11001199Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thymosin alpha 1 and capecitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Recurrence rate, Survival and 1 more. Started Feb 2009; status: completed.
02
Drugs
thymosin alpha 1capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001199.